Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

Delayed Quote. Delayed  - 05/27 09:59:57 pm
4.62 USD   +6.70%
05/19 IMMUNOMEDICS : To report updated results for sacituzumab govitecan (..
05/19 Immunomedics to Report Updated Results for Sacituzumab Govitecan ..
05/04 IMMUNOMEDICS : reports 3Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CEST
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at kristin.jones@dowjones.com

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on IMMUNOMEDICS, INC.
05/19 IMMUNOMEDICS : To report updated results for sacituzumab govitecan (immu-132) in..
05/19 Immunomedics to Report Updated Results for Sacituzumab Govitecan (IMMU-132) i..
05/11 IMMUNOMEDICS INC : Other Events (form 8-K)
05/04 IMMUNOMEDICS : reports 3Q loss
05/04 IMMUNOMEDICS INC : Results of Operations and Financial Condition, Financial Stat..
05/04 Immunomedics Announces Third Quarter Fiscal 2016 Results and Clinical Program..
05/03 IMMUNOMEDICS : Announces Abstract on Sacituzumab Govitecan (IMMU-132) in Patient..
05/02 Immunomedics Announces Abstract on Sacituzumab Govitecan (IMMU-132) in Patien..
04/30 IMMUNOMEDICS : Reports Responses With Sacituzumab Govitecan (IMMU-132) in Patien..
04/29 Immunomedics Reports Responses With Sacituzumab Govitecan (IMMU-132) in Patie..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials